There were improvements in key secondary outcomes: percentage with composite outcome event was lower with caplacizumab (12% vs. 49%, p<0.001) as was percentage with a recurrence of TTP at any time during the trial (12% vs. 38%, p<0.001). Patients who received caplacizumab needed less plasma exchange and had a shorter hospitalisation than those who received placebo.
In Sept 2018, the European Commission granted marketing authorization for Cablivi™ (caplacizumab) for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura.